Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Current Leases (2016 - 2017)

Neurocrine Biosciences (NBIX) has disclosed Current Leases for 8 consecutive years, with $62000.0 as the latest value for Q4 2017.

  • For the quarter ending Q4 2017, Current Leases fell 73.73% year-over-year to $62000.0, compared with a TTM value of $62000.0 through Dec 2017, down 73.73%, and an annual FY2017 reading of $62000.0, down 73.73% over the prior year.
  • Current Leases was $62000.0 for Q4 2017 at Neurocrine Biosciences, down from $121000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $556000.0 in Q2 2015 and bottomed at $62000.0 in Q4 2017.
  • Average Current Leases over 5 years is $352900.0, with a median of $412500.0 recorded in 2013.
  • The sharpest move saw Current Leases surged 84.39% in 2013, then crashed 73.73% in 2017.
  • Year by year, Current Leases stood at $416000.0 in 2013, then increased by 12.26% to $467000.0 in 2014, then decreased by 8.35% to $428000.0 in 2015, then plummeted by 44.86% to $236000.0 in 2016, then plummeted by 73.73% to $62000.0 in 2017.
  • Business Quant data shows Current Leases for NBIX at $62000.0 in Q4 2017, $121000.0 in Q3 2017, and $181000.0 in Q2 2017.